Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Completed 4Terminated 3Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 6CNS 5NET 4Dermatologic 2Head & Neck 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 101Squamous Cell Carcinoma of Head and Neck 76Oropharyngeal Neoplasms 19Carcinoma, Squamous Cell 16Thyroid Neoplasms 15Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Carcinoma 10Neoplasms 9Mouth Neoplasms 9Lung Neoplasms 9Laryngeal Neoplasms 9Tongue Neoplasms 8Stomach Neoplasms 7Salivary Gland Neoplasms 7Neoplasm Metastasis 7Prostatic Neoplasms 6Ovarian Neoplasms 6Nasopharyngeal Carcinoma 6Hypopharyngeal Neoplasms 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Melanoma 5Esophageal Neoplasms 5Pancreatic Neoplasms 4Mucositis 4Carcinoma, Renal Cell 4Xerostomia 3

Interventions

lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Pheochromocytoma × Head & Neck × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡